Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II dose-finding study of BI 456906 in obesity or overweight
2020-002479-37Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in obesity and Overweight comparing BI 456906 once weekly with Placebo once weekly (2 arms). Primary endpoint: Percentage change in body weight from baseline to Week 46. Started Dec 2020; status: completed.
02
Drugs
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on 2020-002479-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002479-37.